Shared Decision Making in Hemophilia Patient Care

The Pfizer Quality Improvement Competitive Grant Program for Shared Decision Making in Hemophilia Patient Care is designed to support quality improvement projects that enhance the interaction between individuals living with hemophilia, their caregivers, and the multidisciplinary teams at hemophilia treatment centers across the United States. Pfizer’s goal with this initiative is to fund projects that integrate shared decision making (SDM) tools and care algorithms into hemophilia patient care, with a strong emphasis on addressing healthcare disparities and empowering patients. The primary purpose of this grant program is to foster effective communication and collaboration between patients and healthcare teams. Projects should focus on implementing SDM tools or care management algorithms in patient care, identifying barriers that contribute to geographic, gender, and racial healthcare disparities, and exploring strategies to enable patients to participate actively in their care decisions. System-based changes are particularly encouraged, although educational components are also acceptable within project designs. Research projects evaluating the efficacy of therapeutic or diagnostic agents are explicitly excluded from this funding opportunity. Eligible applicants include a broad range of healthcare-related organizations such as medical, dental, nursing, allied health, and pharmacy professional schools; healthcare institutions; professional organizations; government agencies; and similar entities. Individual applicants and unaffiliated medical practice groups are not eligible. Collaborations within and between institutions are encouraged, provided all partners play a relevant role and the lead organization assumes a key role in the project. The project lead must be an employee or contractor of the requesting organization, which must also be able to legally accept funding from Pfizer. The grant offers funding for individual projects up to $30,000, with an expected total of two grants awarded. Projects may run for up to 18 months. All awarded funds must cover direct costs, allowable overhead (capped at 28%), and indirect costs, excluding capital expenditures and Pfizer therapeutic agents. The submission deadline for applications is July 23, 2025, with award notifications anticipated in September 2025. Selected projects are expected to commence in November or December 2025 and conclude by May or June 2027. Applications must be submitted via Pfizer’s CyberGrants portal, with strict adherence to submission guidelines, including the use of the specific application portal link provided. Required materials include a detailed project proposal addressing goals, needs assessment, project design and methods, innovation, evaluation and outcomes, timeline, organizational details, and a budget plan. Specific questions and clarifications can be directed to the grant officer, Talita Honorato-Rzeszewicz, via email at talita.honorato-rzeszewicz@pfizer.com. The review and approval process involves an internal Pfizer review to ensure alignment with the grant’s objectives. Approved applicants will enter into a formal grant agreement with Pfizer, and no modifications to the terms will be entertained except in cases of legal conflict. Pfizer emphasizes that it will not influence the design or conduct of funded projects. This initiative is part of Pfizer’s broader commitment to supporting independent quality improvement activities that address unmet medical needs and improve patient outcomes.

Strictly adhere to submission guidelines; use the specified portal; prepare the project plan with required components clearly addressed.